Mohammad Azab has bought XENE on 2 days since Sep 2017

Mohammad Azab, M.D., MSc, MBA, is a biopharmaceutical executive and corporate director who has served as a director of Xenon Pharmaceuticals Inc. (Nasdaq: XENE) from 2003 until June 2024, during which time he has been a reporting corporate insider in his capacity as a board member.( A physician by training with specialist expertise in oncology drug development, he has held senior leadership roles across multiple pharmaceutical and biotech companies, including President and Chief Medical Officer of Astex Pharmaceuticals Inc., President and Chief Executive Officer of Intradigm Corporation, Executive Vice President of Research and Development and Chief Medical Officer at QLT Inc., and leadership positions at AstraZeneca plc in the United Kingdom and Sanofi in France.(

Beyond Xenon, Dr. Azab has built a broad portfolio of board service in the life sciences sector, serving on the boards of Lisata Therapeutics (where he joined the board in September 2022) and DURECT Corporation since 2021, among others.( He holds an MBA from the Richard Ivey School of Business at the University of Western Ontario, an MB ChB (medical degree) from Cairo University, and postgraduate degrees in oncology research from the University of Paris-Sud and in biostatistics from the University of Pierre et Marie Curie in Paris, reflecting a combined clinical, scientific, and business background that underpins his role as a corporate insider and strategic advisor to biopharmaceutical companies.(

Written by Perplexity from public sources.